Xeris Pharmaceuticals Inc (XERS) saw its stock soar 5.02% in intraday trading on Thursday, following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported record-breaking product revenue and provided an optimistic full-year outlook, sparking investor enthusiasm.

Xeris Biopharma announced Q1 product revenue of $57.802 million, slightly surpassing the IBES estimate of $57.6 million. This performance demonstrates the company's ability to meet and exceed market expectations. Despite reporting a net loss of $9.22 million, or $0.06 per basic share, the focus remained on the top-line growth and future prospects.

Adding to the positive sentiment, Xeris Biopharma provided a robust full-year revenue outlook of $260 million to $275 million. This forward-looking guidance suggests continued growth and potential profitability improvements, which likely contributed to the stock's significant uptick. Investors appear to be betting on Xeris' long-term potential, overlooking the current operating loss of $3.09 million as the company continues to invest in its product pipeline and market expansion.